GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt

Names

[ Name ]:
GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt

[Synonym ]:
Glucagon-like peptide 1 (1-37)
Glucagon-like peptide 1 (1-37) (human, rat)
Glucagon-like peptide 1 (1-37), human

Biological Activity

[Description]:

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> Glucagon Receptor

Peptides

Research Areas >> Metabolic Disease

[Target]

GLP-1 receptor[1]

[In Vitro]

Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells[1].

[In Vivo]

GLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group[1].

[Cell Assay]

HEK293 cells (5×104) are seeded in a 96-well plate and transiently cotransfected with the GLP-1R plasmid and the CRE-luciferase reporter plasmid. After a 48 h transfection, different concentrations of GLP-1(1–37) or GLP-1(7–37) are added, and the cells are incubated for 5 h. The cells are harvested for a luciferase assay using a luciferase assay[1].

[Animal admin]

Mice[1] The normal KM mice are fasted for 16 h before the administration (i.p.) of GLP-1 and glucose. GLP-1(1-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is given in combination with glucose (4 g/kg). GLP-1(7-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is also administrated in combination with glucose (4 g/kg). The control group is treated with saline (NaCl, 9 g/l) and glucose (4 g/kg). The IPGTT is carried out at 0, 15, 30 and 60 min after glucose and protein administration, and the blood glucose levels are measured as described above[1].

[References]

[1]. Zhao L, et al. Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice. Regul Pept. 2012 Oct 10;178(1-3):1-5.

[Related Small Molecules]

Chemical & Physical Properties

[ Molecular Formula ]:
C₁₈₆H₂₇₅N₅₁O₅₉

[ Molecular Weight ]:
4169.48

[ Storage condition ]:
−20°C

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

Articles

GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells.

Biochem. Biophys. Res. Commun. 447(1) , 133-8, (2014)

Glucagon-like peptide (GLP)-1 analog based therapies are used not only for their insulinotropic effects, but also for their pleiotropic effects that improve pancreatic β cell function. Liraglutide is ...

Glucagon-like peptide-1 and blood pressure in young and healthy adults from the general population.

Hypertension 65(2) , 306-12, (2015)

Hypertension and diabetes mellitus are highly correlated, but the underlying mechanisms are only partly understood. Therefore, the aim of our study was to investigate the relationships between plasma ...

The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus.

BMC Res. Notes 7 , 849, (2014)

Glucagon like peptide-1 (GLP-1), an incretin hormone, regulates glucose metabolism by inducing insulin secretion and suppressing glucagon secretion. The aim of the study is to assess the levels of fas...